- 询价
- 辰辉创聚生物®️
- 中国
- NBAB-136388
- 2026年05月21日
- IHC
相关产品推荐更多 >
抗人CIDEA多克隆抗体 | Anti-Human CIDEA Polyclonal Antibody
询价抗ZEBOV VP35/Polymerase cofactor VP35抗体 | Anti-ZEBOV VP35/Polymerase cofactor VP35 Antibody
询价
抗CD47单抗 | NebuSelect™ Anti-CD47 Monoclonal Antibody
询价抗Neurochondrin抗体 | Anti-Neurochondrin Polyclonal Antibody
询价抗LAMP1多抗 | Anti-LAMP1 Polyclonal Antibody, NBAB-108551
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 免疫原：
Recombinant Mouse CD169 protein
- 形态：
liquid
- 保存条件：
见COA
- 克隆性：
单克隆
- 保质期：
见COA
- 库存：
大量
- 供应商：
北京辰辉创聚生物技术有限公司
- 应用范围：
IHC
- 抗体英文名：
Anti-CD169 Monoclonal Antibody
- 抗体名：
抗鼠CD169抗体
- 规格：
100ul; 500ul; 1ml
| 产品信息
品名：NebuSelect™ Anti-CD169 Monoclonal Antibody
货号：NBAB-136388
品牌：辰辉创聚生物®️
规格：100ul; 500ul; 1ml
| 产品描述
NebuSelect™ Anti-CD169 Monoclonal Antibody (Cat# NBAB-136388) was produced in Rat immunized with Recombinant Mouse CD169 protein, and it reacts with Mouse. This antibody is validated for IHC.
| 产品属性
Product Category：Rat MAb
Reactivity：Mouse, Rat
Specificity：Mouse CD169
Immunogen：Recombinant Mouse CD169 protein
Isotype：Monoclonal Rat IgG
Purification：Protein A & Protein G Affinity Purification
Buffer：0.2 μm filtered solution in PBS, pH7.4, containing 0.09% Sodium azide, 50% glycerol.
Conjugate：Unconjugated
Applications：IHC
Dilution：IHC 1:50～1:500
Storage：This liquid antibody can be stored at 2℃-8℃ for at least two weeks. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20℃. When reconstituted in sterile pH 7.4 0.01M PBS or antibody diluent, the antibody is stable for at least two weeks at 2-4℃.
For Research Use Only!
To get more information, please contact us freely.
郑重声明：仅用于科学研究，不可用于诊断或治疗。
更多产品细节，请联系我司相关客服人员。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验The Application of Monoclonal Antibodies in the Treatment of Lymphoma
lymphoma treated with a chimeric anti-CD20 mAb, and Maloney and co-workers (2 ) recently reported a 50% response rate in relapsed, low-grade, NHL, with a 10---11 mo duration. Encouragingly, patients in these studies did not raise antibody responses
（杨希峰），Yang CY（杨春瑛） et al. Generation and characterization of monoclonal antibody against HIT3a （抗CD3单克隆抗体HIT3a的制备和特异性鉴定）， Acta Academiae Medicinae Sinicae （中国医学科学院学报），1993， 15：157-162.[6] Xiong D S（熊冬生），Yang C Z（杨纯正），Shao X F（邵晓枫）et al. Generation
monoclonal antibodies have improved responses with minimal toxicities. For instance, Rituximab (chimeric anti-CD20 monoclonal antibody) was the first FDA-approved monoclonal antibody for the treatment of patients with non-Hodgkin’s lymphoma (NHL
技术资料暂无技术资料 索取技术资料
